Search for Clinical Trial Results

Lymphoma, Large-Cell, Anaplastic - 25 Studies Found
Status | Study |
Completed |
Study Name: A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Condition:
Interventions: Drug: brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion |
Completed |
Study Name: Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma Condition: Anaplastic Large-Cell Lymphoma Date: 2004-03-12 Interventions: Drug: SGN-30 (anti-CD30 mAb) |
Terminated |
Study Name: SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma Condition: Anaplastic Large Cell Lymphoma Date: 2006-08-16 Interventions:
|
Withdrawn |
Study Name: A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Condition: Systemic Anaplastic Large-Cell Lymphoma Date: 2015-06-30 Interventions: Drug: crizotinib crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vinc |
Active, not recruiting |
Study Name: Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Condition: Anaplastic Large-cell Lymphoma Date: 2013-07-01 Interventions: Drug: brentuximab vedotin Brentuximab vedotin will be administered as a single intravenous (IV) infusion |
Recruiting |
Study Name: Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) Condition:
Date: 2016-10-18 Interventions: Drug: Brentuximab Vedotin Brentuximab vedotin IV infusion. |
Terminated |
Study Name: Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma Condition:
|
Not yet recruiting |
Study Name: Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Condition:
|
Recruiting |
Study Name: Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma" Condition: Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma Date: 2014-04-17 Interventions: Drug: Brentuximab vedotin (recombinant) Brentuximab vedotin (recombinant) for IV infusion |
Completed |
Study Name: A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma Condition:
Date: 2013-09-23 Interventions:
|